Physician profile
Scott A Newbrough
NPI 1053551234
$3,940.31
in general payments reported to CMS, 2019-2025
19 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $58.60 · 2021: $231 · 2022: $48.38 · 2023: $779 · 2024: $2,233 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928 · Travel and Lodging: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.57 |
| Travel and Lodging | $1,384.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,196.73 | 2023-2024 | |
| Allergan, INC. | $389.21 | 2019-2022 | |
| Polynovo North America LLC | $241.06 | 2023-2024 | Novosorb Btm |
| Sientra, INC. | $238.87 | 2019-2021 | |
| Davol INC. | $223.90 | 2023-2024 | Phasix Mesh |
| Baxter Healthcare | $181.01 | 2023-2025 | Perclot, Tisseel, Artiss |
| Smith+Nephew, INC. | $108.69 | 2023-2025 | Collagenase Santyl, Grafix Pl, Oasis |
| Vertex Pharmaceuticals Incorporated | $84.51 | 2024-2025 | |
| Acera Surgical, INC. | $54.12 | 2024-2025 | Restrata Wound Matrix |
| Astrazeneca Pharmaceuticals LP | $45.16 | 2023 | Andexxa |
| W. L. Gore & Associates, INC. | $29.53 | 2025 | Gore Enform Preperitoneal Biomaterial |
| Avita Medical Americas, LLC | $24.05 | 2024 | |
| Coopersurgical, INC. | $23.71 | 2024 | Insorb |
| Access Pro Medical, LLC | $22.03 | 2025 | Matriderm |
| Tela Bio, INC. | $19.56 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molli Surgical (US) INC | $16.38 | 2023 | |
| Biocomposites INC | $14.66 | 2025 | Stimulan |
| Kci USA, INC. | $13.92 | 2023 | V.A.C. Veraflo, Prevena, V.A.C. Dermatac |
| Kowa Pharmaceuticals America, INC. | $13.21 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Newbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.